Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells

1993 ◽  
Vol 36 (12) ◽  
pp. 1152-1157 ◽  
Author(s):  
Helena R. Chang ◽  
Bahman Chavoshan ◽  
Henry Park
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Cancer Cells ◽  
Human Monoclonal Antibody ◽  
Colon Cancer Cells

Effect of AbGn-7, a glycotope-specific monoclonal antibody, on apoptosis in colon cancer cells and tumor growth in xenograft models

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15118-e15118
Author(s):  
S. Lin ◽  
E. Chiang ◽  
Y. Tsai ◽  
S. Lee ◽  
B. Kuo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Cells ◽  
Parp Cleavage ◽  
Potential Candidate ◽  
Dependent Manner ◽  
Colon Cancer Cells ◽  
Dose Dependent

e15118 Background: While clinical benefit against colorectal cancer has been observed with therapeutic monoclonal antibodies such as bevacizumab, cetuximab and panituzumab, the death rate of advanced colorectal cancer remains high that warrants further development of more potent therapeutics. Methods: A cell-based immunization approach was used to generate monoclonal antibodies against targets expressed on human colorectal cancer cells. A chimeric monoclonal antibody, AbGn-7, was selected and evaluated for the potential clinical use to treat colorectal cancer. Results: Expression of AbGn-7 antigen: Carbohydrate competition assay demonstrated that AbGn-7 recognizes a Lewis-A-like carbohydrate antigen (AbGn-7 antigen). Immunohistochemical studies showed that AbGn-7 antigen is expressed in colorectal cancer tissue. No significant binding could be detected in non-tumor tissues except in the epithelia of GI track. Effector function of AbGn-7: AbGn-7 triggered dose-dependent apoptosis in COLO 205 colon cancer cell. In addition, AbGn-7 elicited potent complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in a dose-dependent manner. Molecular mechanism of apoptosis induced by AbGn-7: Tunel assay, PARP cleavage assay as well as caspase inhibitor studies demonstrated that AbGn-7 induced apoptosis in COLO 205 colon cancer cells via a caspase-independent pathway. Xenograft study: AbGn-7 alone, or in combination with 5FU-Leucovorin, effectively inhibited the growth of COLO 205 xenograft in SCID mice and prolonged their survival. Conclusions: The results of the present study suggest that AbGn-7 is a potential candidate for effective treatment of colorectal cancer. [Table: see text]

A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells

2005 ◽  
Vol 40 (10) ◽  
pp. 945-955 ◽  
Author(s):  
Hidehiko Matsukawa ◽  
Takanori Kanai ◽  
Makoto Naganuma ◽  
Nobuhiko Kamada ◽  
Tadakazu Hisamatsu ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Cell Surface ◽  
Cancer Cells ◽  
Surface Antigen ◽  
Cell Surface Antigen ◽  
Colon Cancer Cells ◽  
A Cell

scholarly journals Conjugation of nanomaterials containing rare-earth ion Tb3+ with CD133 monoclonal antibody and its potentials for labeling colon cancer cells (HT-29)

2020 ◽  
Vol 17 (3) ◽  
pp. 427-433
Author(s):  
Le Nhat Minh ◽  
Vo Trong Nhan ◽  
Nguyen Thi Nga ◽  
Tran Thu Huong ◽  
Phung Thi Kim Hue ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Rare Earth ◽  
Cancer Cells ◽  
Human Colon ◽  
Colon Cancer Cells ◽  
Rare Earth Ion ◽  
Human Colon Cancer ◽  
Ht 29

Nanotechnology is the key technology that brings many important applications in biomedical research.Nanolantanites present high stability, easy fabrication and functionalization. Tb3+ ion-containing nanomaterial, a specific type of nanolantanites, possess great prospects. In addition, cancer stem cells (CSCs) are directlyrelated to drug resistance, metastasis, recurrent cancer, etc. Therefore, CSCs are considered as the target forcancer researching and for discovery of more effective therapies. CD133, a trans-membrane glycoprotein, isone of the typical markers that are found to appear very commonly on the surface of many types of CSCs. Inthis study, CD133 monoclonal antibody (MAb) was cojugated with nanomaterials containing Tb3+. Thecoupling between fluorescented nanomaterials containing Tb3+ ions and CD133 MAb was then incubated withhuman colon cancer cells (HT-29) to evaluate its ability to label CSCs in vitro. The results showed thatnanorods containing rare-earth based Tb3+ ions which were fabricated by hydrothermal method, present thelength of about 300 - 800 nm and the diameter in range of 40 - 50 nm. The Tb3+ nanoparticals also havehexagonal structure of terbium phosphate monohydrate and green illuminant. Tb3+ nanorods were also furthersurface silica coated and amino-silane functionalized. This nanostructure was successfully combined withmonoclonal antibodies against CD133 which labelled the surface marker of HT-29 human colon cancer cells.As a result, the combination of CD133+TbPO4@Silica-NH2 (functionalized surface) showed strongerluminescence than the CD133+TbPO4 unfunctionalized combination.

Sign in / Sign up

Export Citation Format

Share Document